AstraZeneca and Merck Get an FDA Priority Review for Lynparza in Prostate Cancer
AstraZeneca (NYSE: AZN) and Merck (NYSE: MRK) continue their quest to gain additional approvals for their blockbuster cancer drug Lynparza. The duo submitted a new application to the Food and Drug Administration for the drug as a treatment for prostate cancer that's resistant to androgen depletion therapy and has metastasized to other areas of the body.
The FDA gave the application a priority review, which cuts four months off the review cycle. The pharmaceutical companies expect to hear back from the agency in the second quarter of this year although a decision could come earlier.
Image source: Getty Images.
Source Fool.com
